A series of TAA mRNAs were then validated in a mouse cancer model, including gp100 [221], melanoma antigen recognized by T cells 1 (MART1) [222], and tyrosinase-related protein 2 (TRP2) [223,224] in B16F10 melanoma tumors, cytokeratin19 mRNA in Lewis lung cancer [225], and CD133 mRNA in gliomas [226]. The gene discussed is DCT; the disease is central nervous system cancer.